Zaloguj się

Gotowe bibliografie tematyczne / Drug development / Artykuły w czasopismach

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Drug development.

Artykuły w czasopismach na temat „Drug development”

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 25 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Drug development”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Mishra, Hara Prasad, Ayush Goel, Sahil Kumar, Mihir Chauhan, Mrinal Patnaik, and Imaad Rehman. "Drug development hit by war." Journal of Pharmacovigilance and Drug Research 3, no. 2 (2022): 11–15. http://dx.doi.org/10.53411/jpadr.2022.3.2.3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Jadhav, Mr Gahininath Thansing, and Mr Rahul Bhavlal Jadhav. "Drug Discovery and Development Process." International Journal of Research Publication and Reviews 5, no. 1 (2024): 1891–95. http://dx.doi.org/10.55248/gengpi.5.0124.0225.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Sheela, Thorat* Sunita Patil Shubhangi Mali. "Pro-Drug Development." International Journal of Pharmaceutical Sciences 3, no. 3 (2025): 1234–43. https://doi.org/10.5281/zenodo.15019692.

Pełny tekst źródła

Streszczenie:

Prodrugs can provide a flexible approach to enhance the efficacy or safety profile, as well as the poor pharmaceutical and pharmacokinetic features of potential therapeutic candidates as well as, in some situations, clinically authorized drugs. As the prodrugs are inactive form of the drugs which undergoes the metabolism it gives the formation of active compounds which is responsible for the therapeutic activity of drug. Right now the prodrug has more attention in the drug discovery and development. The current article focuses on the overview study of prodrugs like the definition, classificati

Style APA, Harvard, Vancouver, ISO itp.

4

Adukondalu, D., Rajesh Rajesh, Shaik Thaslim, E. Soumya, and M. Chandana. "Regulatory Guidelines for New Drug Development." Pharmaceutics and Pharmacology Research 4, no. 3 (2021): 01–11. http://dx.doi.org/10.31579/2693-7247/046.

Pełny tekst źródła

Streszczenie:

Aim: The aim of present project work is to understand the guidelines and regulatory requirements for investigational new drug and development of new drug Objectives: The objective of current project include Need of a new drug to investigate New drug development targets Understanding the properties of new dug Required protocols for submission of new drug to regulatory authority Regulatory requirements to get approval of new drug.

Style APA, Harvard, Vancouver, ISO itp.

5

Sharma, Bhavik. "DRUG DISCOVERY AND DEVELOPMENT: AN OVERVIEW." INDIAN RESEARCH JOURNAL OF PHARMACY AND SCIENCE 7, no. 2 (2020): 2215–26. http://dx.doi.org/10.21276/irjps.2020.7.2.14.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Agrawal, Shrutidevi, Narisetty Sunil Thomas, Anand Babu Dhanikula, Chaman Lal Kaul, and Ramesh Panchagnula. "Antituberculosis drugs and new drug development." Current Opinion in Pulmonary Medicine 7, no. 3 (2001): 142–47. http://dx.doi.org/10.1097/00063198-200105000-00005.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

GRABOWSKI, H. G. "Issues of Drug Development: Orphan Drugs." Science 228, no. 4702 (1985): 981. http://dx.doi.org/10.1126/science.228.4702.981.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Vaalburg, Willem, N. Harry Hendrikse, and Erik F. J. de Vries. "Drug development, radiolabeled drugs and PET." Annals of Medicine 31, no. 6 (1999): 432–37. http://dx.doi.org/10.3109/07853899908998801.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Flaherty, Keith T., Dung T. Le, and Steven Lemery. "Tissue-Agnostic Drug Development." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 222–30. http://dx.doi.org/10.1200/edbk_173855.

Pełny tekst źródła

Streszczenie:

The U.S. Food and Drug Administration (FDA) has approved drugs to treat patients with tumor types based on a single anatomic site, such as renal cell carcinoma or melanoma, rather than on a biomarker alone. This standard approach is based on a number of factors, including heterogeneity of drug effects in different biomarker-positive tumor types. Additionally, drug development for some drugs was primarily directed toward a specific genomic abnormality in a specific tumor type (e.g., drugs for anaplastic lymphoma kinase [ALK] fusion-positive non–small cell lung cancer). In such cases, difference

Style APA, Harvard, Vancouver, ISO itp.

10

Yamashiro, Yuichiro, Jennifer Martin, Madlen Gazarian, et al. "Drug Development." Journal of Pediatric Gastroenterology and Nutrition 55, no. 5 (2012): 506–10. http://dx.doi.org/10.1097/mpg.0b013e318272af1f.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Williams, Ian. "Drug Development." Science 277, no. 5322 (1997): 17.6–21. http://dx.doi.org/10.1126/science.277.5322.17-f.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Williams;, I. "Drug Development." Science 277, no. 5322 (1997): 17e—21. http://dx.doi.org/10.1126/science.277.5322.17e.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

BRENNAN, MAIRIN. "DRUG DEVELOPMENT." Chemical & Engineering News 74, no. 44 (1996): 10. http://dx.doi.org/10.1021/cen-v074n044.p009.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

HENRY, CELIA M. "DRUG DEVELOPMENT." Chemical & Engineering News 80, no. 21 (2002): 53–66. http://dx.doi.org/10.1021/cen-v080n021.p053.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

K. Kapoor, Vijay, and Amanpreet Kaur. "Drug-Glycosidation and Drug Development." Mini-Reviews in Medicinal Chemistry 13, no. 4 (2013): 584–96. http://dx.doi.org/10.2174/1389557511313040010.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Komatsu, Kanji. "Statistical Models for Model-Based Drug Development." Japanese Journal of Biometrics 32, Special_Issue_2 (2011): 179–93. http://dx.doi.org/10.5691/jjb.32.179.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Bhusare, Shubham, Ms Dipmala Ghorpade, and Dr Gajanan Sanap. "Artificial Intelligence in Drug Discovery and Development." International Journal of Research Publication and Reviews 6, no. 1 (2025): 1096–106. https://doi.org/10.55248/gengpi.6.0125.0307.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Garepally, Prasad, Swathi Goli, and Vijay Kumar Bontha. "Design, Development and Characterizations of Acyclovir Osmotic Tablets." Pharmaceutics and Pharmacology Research 1, no. 1 (2018): 01–14. http://dx.doi.org/10.31579/2693-7247/005.

Pełny tekst źródła

Streszczenie:

Oral drug delivery is the most widely utilized route of administration, among all the routes of administration. That has been explored for the systemic delivery drug through different pharmaceutical dosage forms. It can be said that at least 90%of all drugs used to produce systemic effect is by oral route. Conventional oral drug delivery systems are known to provide an immediate release of drug, in which one cannot control the release of the drug and effective concentration at the target site.

Style APA, Harvard, Vancouver, ISO itp.

19

DiMasi, Joseph A., and Henry G. Grabowski. "Economics of New Oncology Drug Development." Journal of Clinical Oncology 25, no. 2 (2007): 209–16. http://dx.doi.org/10.1200/jco.2006.09.0803.

Pełny tekst źródła

Streszczenie:

Purpose Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. Methods We utilized data from the US Food and Drug Administration (FDA), company surveys, and publicly available commercial business intelligence databases on new oncology drugs approved in the United States and on investigational oncology drugs to estimate average development and regulatory approval times, clinical approval success rates, first-in-class status, and global market diffusion. Results We found that approved new oncology drugs to have a dispr

Style APA, Harvard, Vancouver, ISO itp.

20

Drews, Jürgen, and Stefan Ryser. "Drug Development: The role of innovation in drug development." Nature Biotechnology 15, no. 13 (1997): 1318–19. http://dx.doi.org/10.1038/nbt1297-1318.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Kusuhara, Hiroyuki. "Development of endogenous biomarkers to assess drug-transporter-mediated drug-drug interactions in drug development." Proceedings for Annual Meeting of The Japanese Pharmacological Society 94 (2021): 3—S32–4. http://dx.doi.org/10.1254/jpssuppl.94.0_3-s32-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

AMIN, Dipti, and Jean-Pierre ISAL. "Evaluation of Drug-Drug Interactions in Drug Development." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 34, no. 1 (2003): 193S—194S. http://dx.doi.org/10.3999/jscpt.34.193s.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Gandhi, Karan, Umang Shah, and Sandip Patel. "Drug Stereochemistry: A Prodigy For Pharmacology and Drug Development." Current Drug Discovery Technologies 17, no. 5 (2020): 565–73. http://dx.doi.org/10.2174/1570163816666190502101803.

Pełny tekst źródła

Streszczenie:

Stereochemistry has evinced the importance of many chiral drugs with respect to drug designing and development. A literature review was conducted for several chiral drugs involving pharmacokinetic and pharmacodynamic parameters of their enantiomers along with their uses in certain diseased conditions. This article mainly includes the pharmacological profile review of some chiral drugs and the aspects due to which the single enantiomer is of importance as compared to the racemic mixture of the drug. This was achieved by moderating the side effects or toxic effects; or by the potentiated activit

Style APA, Harvard, Vancouver, ISO itp.

24

Rehan Haider, Asghar Mehdi, Anjum Zehra, Geetha Kumari Das, Zameer Ahmed, and Sambreen Zameer. "Drug Development Research in Women." International Journal of Scientific Multidisciplinary Research 2, no. 5 (2024): 415–40. http://dx.doi.org/10.55927/ijsmr.v2i5.8807.

Pełny tekst źródła

Streszczenie:

Drug research in wives is a critical district that has acquired growing consideration in recent ages. Historically, mothers have diminished in clinical tests, chief to a lack of understanding about in what way or manner drugs influence them otherwise distinguished to brothers. This information gap has important associations for drug security and efficiency, as physiological dissimilarities between genders can impact drug absorption, productiveness, and adverse belongings. In answer, skilled has existed a growing importance on containing girls in dispassionate trials and attending grammar princ

Style APA, Harvard, Vancouver, ISO itp.

25

Matsubara, Takashi. "Safety Evaluation and Drug Development based on Biological Fate of Drugs —Efforts Made to Overcome Drug Interaction in Drug Development—." Drug Metabolism and Pharmacokinetics 17, no. 5 (2002): 379–94. http://dx.doi.org/10.2133/dmpk.17.379.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Eunike, Seleky, Santoso Dedy, and Wisnubroto Aloysius. "The Development of Narcotics Legislation in Indonesia and Singapore." International Journal of Social Science And Human Research 06, no. 06 (2023): 3762–67. https://doi.org/10.5281/zenodo.8085856.

Pełny tekst źródła

Streszczenie:

Since the Dutch colonial era, Indonesia has had drug-related regulations. Drug use was controlled with special licenses for people of Chinese descent who contributed financially through the opium trade. After Indonesia's independence, regulations on the production, use, and distribution of dangerous drugs were issued. In the 1970s, drug abuse increased, and the government responded with laws regulating illicit drug trafficking and imposing severe criminal sanctions, including the death penalty. During the Reformasi era, the crackdown on drugs became more assertive. BNN was established in 2

Style APA, Harvard, Vancouver, ISO itp.

27

Shafer, Robert W., and Jonathan M. Schapiro. "Drug resistance and antiretroviral drug development." Journal of Antimicrobial Chemotherapy 55, no. 6 (2005): 817–20. http://dx.doi.org/10.1093/jac/dki127.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

GAD, S. "Active drug metabolites in drug development." Current Opinion in Pharmacology 3, no. 1 (2003): 98–100. http://dx.doi.org/10.1016/s1471-4892(02)00003-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

GS, Lavekar. "Concept of Integrated Drugs Development." Journal of Natural & Ayurvedic Medicine 7, no. 3 (2023): 1–4. http://dx.doi.org/10.23880/jonam-16000413.

Pełny tekst źródła

Streszczenie:

Drugs are an integral part of treatment in health care, it is a belief that the drugs should be free from side effects should be safe and not to create any disease. The chemical or allopathic drugs which are having some side effects may be combined with Ayurveda herbal drugs to pacify their side effects or bring to minimal level. Another aspect is that the Ayurved herbal drugs are slow and weak in action, but quite safe, on other side the allopathic drugs are comparatively fast, bit strong but with some side effects. If these two are combined like an example of anti-diabetic allopathic drug me

Style APA, Harvard, Vancouver, ISO itp.

30

Li, Xue, Xiaoming Fan, Zhu Li, et al. "Application of Microfluidics in Drug Development from Traditional Medicine." Biosensors 12, no. 10 (2022): 870. http://dx.doi.org/10.3390/bios12100870.

Pełny tekst źródła

Streszczenie:

While there are many clinical drugs for prophylaxis and treatment, the search for those with low or no risk of side effects for the control of infectious and non-infectious diseases is a dilemma that cannot be solved by today’s traditional drug development strategies. The need for new drug development strategies is becoming increasingly important, and the development of new drugs from traditional medicines is the most promising strategy. Many valuable clinical drugs have been developed based on traditional medicine, including drugs with single active ingredients similar to modern drugs and tho

Style APA, Harvard, Vancouver, ISO itp.

31

Alderton, Gemma. "Diversifying drug development." Science 371, no. 6529 (2021): 580.9–582. http://dx.doi.org/10.1126/science.371.6529.580-i.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Field, Hugh J., and Mark A. Wainberg. "Antiviral drug development." Future Virology 6, no. 5 (2011): 545–47. http://dx.doi.org/10.2217/fvl.11.36.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Loadman, P. "Anticancer Drug Development." British Journal of Cancer 86, no. 10 (2002): 1665–66. http://dx.doi.org/10.1038/sj.bjc.6600309.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Vaughan Williams, E. M. "ANTIARRHYTHMIC DRUG DEVELOPMENT." American Journal of Therapeutics 2, no. 4 (1995): 233–36. http://dx.doi.org/10.1097/00045391-199504000-00002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Somberg, John C. "Pediatric Drug Development." American Journal of Therapeutics 10, no. 1 (2003): 2. http://dx.doi.org/10.1097/00045391-200301000-00002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Donnan, Geoffrey A., and Stephen M. Davis. "Stroke Drug Development." Stroke 36, no. 10 (2005): 2326. http://dx.doi.org/10.1161/01.str.0000179042.06535.2f.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Luetkemeyer, Anne F., Haileyesus Getahun, Gabriel Chamie, Christian Lienhardt, and Diane V. Havlir. "Tuberculosis Drug Development." American Journal of Respiratory and Critical Care Medicine 184, no. 10 (2011): 1107–13. http://dx.doi.org/10.1164/rccm.201106-0995pp.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Ades, Felipe, Dimitrios Zardavas, Philippe Aftimos, and Ahmad Awada. "Anticancer drug development." Current Opinion in Oncology 26, no. 3 (2014): 334–39. http://dx.doi.org/10.1097/cco.0000000000000076.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Preskorn, Sheldon H. "CNS Drug Development." Journal of Psychiatric Practice 16, no. 6 (2010): 413–15. http://dx.doi.org/10.1097/01.pra.0000390760.12204.99.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Preskorn, Sheldon H. "CNS Drug Development." Journal of Psychiatric Practice 17, no. 1 (2011): 49–52. http://dx.doi.org/10.1097/01.pra.0000393844.48593.82.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

PRESKORN, SHELDON H. "CNS Drug Development." Journal of Psychiatric Practice 20, no. 6 (2014): 460–65. http://dx.doi.org/10.1097/01.pra.0000456594.66363.6f.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

PRESKORN, SHELDON H. "CNS Drug Development." Journal of Psychiatric Practice 21, no. 1 (2015): 60–66. http://dx.doi.org/10.1097/01.pra.0000460622.33300.64.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Kaye, Stanley B. "New drug development." European Journal of Cancer and Clinical Oncology 27, no. 3 (1991): 377–80. http://dx.doi.org/10.1016/0277-5379(91)90550-w.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

McConnell, John. "Global drug development?" Lancet 341, no. 8848 (1993): 822. http://dx.doi.org/10.1016/0140-6736(93)90592-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Hoffman, Steven J., Thomas Pogge, and Aidan Hollis. "New drug development." Lancet 377, no. 9769 (2011): 901–2. http://dx.doi.org/10.1016/s0140-6736(11)60347-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Catalá-López, Ferrán, Anna García-Altés, Elena Álvarez-Martín, Ricard Gènova-Maleras, and Consuelo Morant-Ginestar. "New drug development." Lancet 377, no. 9769 (2011): 902. http://dx.doi.org/10.1016/s0140-6736(11)60348-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Walson, Philip D. "Pediatric Drug Development." Clinical Therapeutics 36, no. 2 (2014): 154–55. http://dx.doi.org/10.1016/j.clinthera.2014.01.012.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Novack, Gary D. "Ophthalmic Drug Development." Journal of Glaucoma 7, no. 3 (1998): 202???209. http://dx.doi.org/10.1097/00061198-199806000-00009.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Katz, Linda M. "Nonprescription Drug Development." Drug Information Journal 28, no. 2 (1994): 449–51. http://dx.doi.org/10.1177/009286159402800218.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Schachter, Asher D., and Marco F. Ramoni. "Paediatric drug development." Nature Reviews Drug Discovery 6, no. 6 (2007): 429–30. http://dx.doi.org/10.1038/nrd2333.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!